Atlas Trials

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Clinical trial NCT04802590 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04802590
Sponsor
The Lymphoma Academic Research Organisation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2022-01-24
Primary completion
2028-03-31
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.